A nonclassical vitamin D receptor pathway suppresses renal fibrosis

Journal of Clinical Investigation

Volumn 123, Issue 11, 2013, Pages 4579-4594

  Ito, Ichiaki ^a   Waku, Tsuyoshi ^b   Aoki, Masato ^a   Abe, Rumi ^c   Nagai, Yu ^c   Watanabe, Tatsuya ^a   Nakajima, Yuka ^a   Ohkido, Ichiro ^d   Yokoyama, Keitaro ^d   Miyachi, Hiroyuki ^e   Shimizu, Toshiyuki ^b   Murayama, Akiko ^a   Kishimoto, Hiroyuki ^a   Nagasawa, Kazuo ^c   Yanagisawa, Junn ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Japan)

^d JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e OKAYAMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CALCIUM; CALVASCULIN; FOLIC ACID; PARICALCITOL; SMAD PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; VITAMIN D RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; DNA BINDING; HYPERCALCEMIA; IMMUNOFLUORESCENCE; KIDNEY FIBROSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; URETER OBSTRUCTION; WESTERN BLOTTING;

EID: 84887459688     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI67804     Document Type: Article

References (65)

1. Sporn MB, Roberts AB. TGF-β: problems and prospects. Cell Regul. 1990;1(12):875-882.
2. Roberts AB, Sporn MB. Physiological actions and clinical applications of transforming growth factor-beta (TGF-β). Growth Factors. 1993;8(1):1-9.
3. Feng XH, Derynck R. Specificity and versatility in tgf-beta signaling through Smads. Annu Rev Cell Dev Biol. 2005;21:659-693.
4. Massague J, Seoane J, Wotton D. Smad transcription factors. Genes Dev. 2005;19(23):2783-2810.
5. Luo K, Lodish HF. Positive and negative regulation of type II TGF-β receptor signal transduction by autophosphorylation on multiple serine residues. EMBO J. 1997;16(8):1970-1981.
6. Wrana JL, Attisano L, Wieser R, Ventura F, Massague J. Mechanism of activation of the TGF-β receptor. Nature. 1994;370(6488):341-347.
7. Heldin CH, Miyazono K, ten Dijke P. TGF-β signalling from cell membrane to nucleus through SMAD proteins. Nature. 1997;390(6659):465-471.
8. Abdollah S, Macias-Silva M, Tsukazaki T, Hayashi H, Attisano L, Wrana JL. TβRI phosphorylation of Smad2 on Ser465 and Ser467 is required for Smad2-Smad4 complex formation and signaling. J Biol Chem. 1997;272(44):27678- 27685.
9. Liu X, Sun Y, Constantinescu SN, Karam E, Weinberg RA, Lodish HF. Transforming growth factor β-induced phosphorylation of Smad3 is required for growth inhibition and transcriptional induction in epithelial cells. Proc Natl Acad Sci U S A. 1997; 94(20):10669-10674.
10. Eppert K, et al. MADR2 maps to 18q21 and encodes a TGFβ-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell. 1996;86(4):543-552.
11. Lagna G, Hata A, Hemmati-Brivanlou A, Massague J. Partnership between DPC4 and SMAD proteins in TGF-β signalling pathways. Nature. 1996; 383(6603):832-836.
12. Zhang Y, Feng X, We R, Derynck R. Receptor-associated Mad homologues synergize as effectors of the TGF-β response. Nature. 1996;383(6596):168- 172.
13. Zhang YE. Non-Smad pathways in TGF-β signaling. Cell Res. 2009;19(1):128-139.
14. Noble NA, Border WA. Angiotensin II in renal fibrosis: should TGF-β rather than blood pressure be the therapeutic target? Semin Nephrol. 1997; 17(5):455-466.
15. Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β 1. Nature. 1990;346(6282):371-374.
16. Gaedeke J, Peters H, Noble NA, Border WA. Angiotensin II, TGF-β and renal fibrosis. Contrib Nephrol. 2001; (135):153-160.
17. Zeisberg M, Neilson EG. Mechanisms of tubulointerstitial fibrosis. J Am Soc Nephrol. 2010; 21(11):1819-1834.
18. Okuda S, Languino LR, Ruoslahti E, Border WA. Elevated expression of transforming growth factor-β and proteoglycan production in experimental glomerulonephritis. Possible role in expansion of the mesangial extracellular matrix. J Clin Invest. 1990;86(2):453-462.
19. Massague J. TGFβ in cancer. Cell. 2008; 134(2):215-230.
20. Eddy AA. Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol. 1996;7(12):2495-2508.
21. Klahr S, Morrissey J. Obstructive nephropathy and renal fibrosis. Am J Physiol Renal Physiol. 2002;83(5):F861-F875.
22. Chevalier RL, Forbes MS, Thornhill BA. Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy. Kidney Int. 2009; 5(11):1145-1152.
23. Klein J, et al. Renal fibrosis: insight from proteomics in animal models and human disease. Proteomics. 2011;1(8):805-815.
24. Flanders KC, et al. Mice lacking Smad3 are protected against cutaneous injury induced by ionizing radiation. Am J Pathol. 2002;60(3):1057-1068.
25. Schnabl B, Kweon YO, Frederick JP, Wang XF, Rippe RA, Brenner DA. The role of Smad3 in mediating mouse hepatic stellate cell activation. Hepatology. 2001;4(1):89-100.
26. Sato M, Muragaki Y, Saika S, Roberts AB, Ooshima A. Targeted disruption of TGF-β1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J Clin Invest. 2003;112(10):1486-1494.
27. Inazaki K, et al. Smad3 deficiency attenuates renal fibrosis, inflammation, and apoptosis after unilateral ureteral obstruction. Kidney Int. 2004;6(2):597-604.
28. Fujimoto M, et al. Mice lacking Smad3 are protected against streptozotocin-induced diabetic glomerulopathy. Biochem Biophys Res Commun. 2003; 05(4):1002-1007.
29. Zhao J, et al. Smad3 deficiency attenuates bleomycin-induced pulmonary fibrosis in mice. Am J Physiol Lung Cell Mol Physiol. 2002;82(3):L585-L593.
30. Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J. 1996;0(9):940-954.
31. Mangelsdorf DJ, et al. The nuclear receptor superfamily: the second decade. Cell. 1995;83(6):835-839.
32. McKenna NJ, O'Malley BW. Combinatorial control of gene expression by nuclear receptors and coregulators. Cell. 2002;108(4):465-474.
33. Tora L, et al. The human estrogen receptor has two independent nonacidic transcriptional activation functions. Cell. 1989;59(3):477-487.
34. Rochel N, Wurtz JM, Mitschler A, Klaholz B, Moras D. The crystal structure of the nuclear receptor for vitamin D bound to its natural ligand. Mol Cell. 2000; 5(1):173-179.
35. Heery DM, Kalkhoven E, Hoare S, Parker MG. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature. 1997; 387(6634):733-736.
36. Szpirer J, et al. The Sp1 transcription factor gene (SP1) and the 1,25-dihydroxyvitamin D3 receptor gene (VDR) are colocalized on human chromosome arm 12q and rat chromosome 7. Genomics. 1991; 11(1):168-173.
37. Palmer HG, et al. Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of β-catenin signaling. J Cell Biol. 2001;154(2):369-387.
38. Shah S, et al. The molecular basis of vitamin D receptor and β-catenin crossregulation. Mol Cell. 2006; 21(6):799-809.
39. Haussler MR, Jurutka PW, Mizwicki M, Norman AW. Vitamin D receptor (VDR)-mediated actions of 1α,25(OH)(2)vitamin D(3): genomic and nongenomic mechanisms. Best Pract Res Clin Endocrinol Metab. 2011;25(3):543-559.
40. Levi M. Nuclear receptors in renal disease. Biochim Biophys Acta. 2011;1812(8):1061-1067.
41. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest. 2002;110(2):229-238.
42. Li Y, Spataro BC, Yang J, Dai C, Liu Y. 1,25-dihydroxyvitamin D inhibits renal interstitial myofibroblast activation by inducing hepatocyte growth factor expression. Kidney Int. 2005; 68(4):1500-1510.
43. Yuan W, et al. 1,25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J Biol Chem. 2007;282(41):29821-29830.
44. Zhang Z, et al. 1,25-Dihydroxyvitamin D3 targeting of NF-κB suppresses high glucose-induced MCP-1 expression in mesangial cells. Kidney Int. 2007;72(2):193-201.
45. Freundlich M, et al. Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Kidney Int. 2008;74(11):1394-1402.
46. Tan X, Wen X, Liu Y. Paricalcitol inhibits renal inflammation by promoting vitamin D receptormediated sequestration of NF-κB signaling. J Am Soc Nephrol. 2008;19(9):1741-1752.
47. Deb DK, et al. 1,25-Dihydroxyvitamin D3 suppresses high glucose-induced angiotensinogen expression in kidney cells by blocking the NF-κB pathway. Am J Physiol Renal Physiol. 2009; 296(5):F1212-F1218.
48. Zhang Y, Kong J, Deb DK, Chang A, Li YC. Vitamin D receptor attenuates renal fibrosis by suppressing the renin-angiotensin system. J Am Soc Nephrol. 2010; 21(6):966-973.
49. Tan X, Li Y, Liu Y. Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol. 2006;17(12):3382-3393.
50. Samarakoon R, Overstreet JM, Higgins SP, Higgins P. J. TGF-β1 → SMAD/p53/USF2 → PAI-1 transcriptional axis in ureteral obstruction-induced renal fibrosis. Cell Tissue Res. 2011;347(1):117-128.
51. Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S, Gauthier JM. Direct binding of Smad3 and Smad4 to critical TGFβ-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J. 1998;17(11):3091-3100.
52. Alroy I, Towers TL, Freedman LP. Transcriptional repression of the interleukin-2 gene by vitamin D3: direct inhibition of NFATp/AP-1 complex formation by a nuclear hormone receptor. Mol Cell Biol. 1995; 15(10):5789-5799.
53. Ishizuka S, Sato J, Takahama S, Seino Y, Norman AW. Serum concentrations of 1α,25(OH)2D3-26,26-lactone in normal adults. In: Norman AW, Bouillon R, Thomasset M, eds. Vitamin D: Gene Regulation, Structure-Function Analysis and Clinical Application. Berlin, Germany: Walter de Gruyter; 1991:300-301.
54. Nakano Y, et al. Practical synthesis and evaluation of the biological activities of 1α,25-dihydroxyvitamin D3 antagonists, 1α,25- dihydroxyvitamin D3-26,23-lactams. Designed on the basis of the helix 12-folding inhibition hypothesis. J Med Chem. 2006;49(8):2398-2406.
55. Robinson DM, Scott LJ. Paricalcitol: a review of its use in the management of secondary hyperparathyroidism. Drugs. 2005;65(4):559-576.
56. Bechtel W, et al. Methylation determines fibroblast activation and fibrogenesis in the kidney. Nat Med. 2010;16(5):544-550.
57. Ohnuma N, Bannai K, Yamaguchi H, Hashimoto Y, Norman AW. Isolation of a new metabolite of vitamin D produced in vivo, 1α,25-dihydroxyvitamin D3-26,23-lactone. Arch Biochem Biophys. 1980; 204(1):387-391.
58. Ishizuka S, Norman AW. Metabolic pathways from 1α,25- dihydroxyvitamin D3 to 1α,25-dihydroxyvitamin D3-26,23-lactone. Stereo-retained and stereo-selective lactonization. J Biol Chem. 1987; 262(15):7165-7170.
59. Horst RL, Wovkulich PM, Baggiolini EG, Uskokovic MR, Engstrom GW, Napoli JL. (23S)-1,23,25-Trihydroxyvitamin D3: its biologic activity and role in 1α,25-dihydroxyvitamin D3 26,23-lactone biosynthesis. Biochemistry. 1984;23(17):3973-3979.
60. Cianferotti L, Marcocci C. Subclinical vitamin D deficiency. Best Pract Res Clin Endocrinol Metab. 2012; 26(4):523-537.
61. Ding N, et al. A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response. Cell. 2013; 153(3):601-613.
62. Ito I, et al. Estrogen inhibits transforming growth factor β signaling by promoting Smad2/3 degradation. J Biol Chem. 2010;285(19):14747- 14755.
63. Zawel L, et al. Human Smad3 and Smad4 are sequence-specific transcription activators. Mol Cell. 1998;1(4):611-617.
64. Shi Y, Wang YF, Jayaraman L, Yang H, Massague J, Pavletich NP. Crystal structure of a Smad MH1 domain bound to DNA: insights on DNA binding in TGF-β signaling. Cell. 1998;94(5):585-594.
65. Zeisberg EM, Potenta SE, Sugimoto H, Zeisberg M, Kalluri R. Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J Am Soc Nephrol. 2008;19(12):2282-2287.